Home > Boards > US OTC > Biotechs > Oxford BioMedica PLC (OXBDF)

Digital tech from Autolus and Oxford BioMedica to

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
marcusl2 Member Profile
 
Followed By 2
Posts 426
Boards Moderated 0
Alias Born 01/14/14
160x600 placeholder
marcusl2   Thursday, 11/22/18 11:41:18 AM
Re: None
Post # of 749 
Digital tech from Autolus and Oxford BioMedica to speed advanced therapies
UK funds efforts to make country a leader in cell and gene therapy

Also receiving funding is Oxford BioMedica, one of the UK’s leading manufacturers of cell and gene therapies, best know for supplying the lentiviral vector used in Novartis’ CAR-T therapy Kymriah.

The three companies will share a £4.3m Digitalisation of Medicines Manufacturing fund from the government Department for Business, Enterprise and Industrial Strategy, (BEIS) which aims to create more efficient and innovative methods for manufacturing medicines.

Oxford Biomedica will look to dramatically reduce the supply time for manufacturing by using a new digital and robotics framework to increase capacity, reduce waste and cut costs.

HTTp://www.pmlive.com/pharma_news/digital_tech_from_autolous_and_oxford_biomedica_to_speed_advanced_therapies_1262473

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist